VivoSim Labs, Inc. (VIVS)
VivoSim Labs, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
VivoSim Labs, Inc. (VIVS) is a Biotechnology company based in US with a market capitalization of $3.4M. Revenue grew 32.1% year-over-year and free cash flow was negative at -$9.5M. This page tracks VIVS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 14 employees · IPO Feb 14, 2012
Valuation
Valuation & price
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$3.4M
Market cap
32.1%
Revenue growth (YoY)
96.5%
Gross margin
-$9.5M
Free cash flow (USD)
-$10.4M
Net debt
Net cash position
92.1%
Share dilution
—
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 29, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventApr 3, 2026Filing
Public Offering Priced
Questions
Frequently asked questions
What is VivoSim Labs, Inc.'s market cap?
VivoSim Labs, Inc. (VIVS) has a market capitalization of $3.4M.
When did VivoSim Labs, Inc. last report earnings?
VIVS last reported earnings on May 29, 2026; the next date is not yet scheduled.
Are insiders buying VIVS stock?
SEC Form 4 filings show no open-market insider buys at VivoSim Labs, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.